End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
59.91 CNY | -3.04% | +4.81% | -12.12% |
Apr. 29 | Jefferies Adjusts Yunnan Botanee Bio-Technology’s Price Target to 62 Yuan From 87 Yuan, Keeps at Hold | MT |
Apr. 26 | Yunnan Botanee Bio-Technology Group Co.LTD Proposes Final Dividend for 2023 | CI |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
- From a short-term investment perspective, the company presents a deteriorated fundamental configuration.
Strengths
- Growth is a substantial asset for the company, as anticipated by dedicated analysts. Within the next three years, growth is estimated to reach 66% by 2026.
- The group's high margin levels account for strong profits.
- Thanks to a sound financial situation, the firm has significant leeway for investment.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
Weaknesses
- In relation to the value of its tangible assets, the company's valuation appears relatively high.
- The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.
- For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
- The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.
- For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
- For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.
- The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
- The average consensus view of analysts covering the stock has deteriorated over the past four months.
- Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
- The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.
- The group usually releases earnings worse than estimated.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Personal Products
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-12.12% | 3.49B | C+ | ||
+19.64% | 20.69B | B+ | ||
0.00% | 18.4B | - | - | |
+6.07% | 11.56B | A- | ||
-10.06% | 9.69B | A- | ||
+17.79% | 7.66B | B+ | ||
+14.08% | 6.19B | B | ||
+2.13% | 4.62B | B+ | ||
-15.27% | 3.91B | C- | ||
-4.59% | 3.69B | B |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- 300957 Stock
- Ratings Yunnan Botanee Bio-Technology Group Co.LTD